Stopped losing weight on Wegovy 2.4mg: what's happening and what to do next

Why the scales stop moving at 2.4mg

Semaglutide reduces appetite and slows how quickly food leaves the stomach. Early in treatment, that effect is new to your body and the calorie reduction tends to be substantial. Over months, the body recalibrates: it lowers its resting energy expenditure to match the reduced intake, a process sometimes called adaptive thermogenesis. This is not a flaw in the medicine or in you. It is the same biological defence mechanism that operates after any sustained calorie deficit, whether the cause is a weight-loss drug, a change in diet, or both.

At 2.4mg specifically, you are at the licensed maintenance dose for the injection. There is no higher rung on the original schedule, which means the pharmacological effect is not going to intensify further under the standard titration. That context matters when you are deciding what to do next, because the options are meaningfully different depending on whether the plateau is recent or has persisted for six months or more. You might find it useful to read about the full Wegovy dosing schedule to place 2.4mg in perspective.

Lifestyle factors also compound the picture. As you lose weight your total daily energy needs fall, so the same eating habits that produced a deficit at the start eventually become maintenance-level calories. Regular movement and adequate protein intake help counteract some of this drift, though the specifics are for a dietitian or your prescriber to advise on.

What NICE says about continuing beyond a plateau

The NICE technology appraisal for semaglutide (TA875) recommends considering whether to continue treatment if a patient has not achieved at least 5% weight loss after six months on the maintenance dose. That threshold is a clinical review point, not an automatic stop. It means your prescriber should assess whether the medicine is still delivering meaningful benefit when weighed against cost, side effects and your individual circumstances.

If you are still losing weight slowly, or maintaining a loss that has a genuine health benefit, that picture looks different from a true plateau with no movement over many months. The six-month figure is important context: a two- or three-week stall is not the same clinical situation as six months without progress. Keeping an honest record of your weight over time, even just checking weekly on the same scale before breakfast, gives your prescriber the data they actually need to advise you well.

For a detailed look at what happens when 2.4mg simply stops producing results over a longer period, the page on Wegovy stopped working at 2.4mg covers that distinct scenario.

The 7.2mg dose: a newer option worth discussing with your clinician

In April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, following earlier approval of the 7.2mg dose itself in January 2026. Trial data reported an average weight loss of around 20.7% over 72 weeks at 7.2mg, which is meaningfully higher than results at 2.4mg and begins to approach the figures seen with tirzepatide at its higher doses. The 7.2mg pen is licensed for adults with a BMI of 30 or above.

This is not a self-managed step up. The starting dose remains 0.25mg, titrated gradually; the 7.2mg pen is the new ceiling for patients who tolerate the journey there. Whether it is appropriate for someone who plateaued at 2.4mg is a clinical question, not a formulaic one. Your prescriber will consider your response so far, any side effects you have experienced, and your overall health. The MHRA's announcement on the 7.2mg pen sets out the approval in full.

If you are weighing Wegovy against other licensed options, or looking at cost context alongside clinical fit, the Wegovy pricing page explains what private treatment typically involves financially.

Making the decision: what a prescriber needs from you

The decision is rarely binary. Stopping, continuing at 2.4mg, stepping up toward 7.2mg, or switching to a different licensed medicine are all possibilities, and the right one depends on information only your clinician can properly weigh. What helps them most is a clear account of how long the plateau has lasted, what your diet and activity have looked like during that period, whether side effects have eased off or are still limiting you, and what you were hoping to achieve when you started treatment.

One thing our prescribers hear fairly often is that patients have quietly reduced their dose to manage nausea, or skipped a week here and there, without flagging it. That changes the clinical picture considerably. Honesty about how the treatment has actually been going is more useful than the version that looks tidy on paper. If you have had any missed doses, the page on what happens with a missed Wegovy dose covers the practical guidance around that.

For anyone on an earlier dose wondering whether a plateau is dose-related, the same pattern can appear at lower points in the titration schedule, as explored on our page about not losing weight on 1.7mg Wegovy. And if you would like a clinician to look at your specific situation, you are welcome to speak to our prescribers through a free consultation.